US Oncology 8-K Regulation FD Disclosure

Exhibit 99.1

Summary of Historical Condensed Consolidated Financial Information

The summary historical consolidated financial and other data presented below should be read in conjunction with “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and the consolidated financial statements and the related notes thereto contained in our Current Report on Form 8-K filed on June 4, 2009 (which retrospectively adjusted the audited Financial Statements and Supplemental Data in our Annual Report on Form 10-K for the year ended December 31, 2008) and the Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2009, which are incorporated by reference herein. The summary historical consolidated financial data and other data set forth below for, and as of the end of the fiscal years ended December 31, 2006, 2007 and 2008 have been derived from our audited consolidated financial statements. The summary historical consolidated financial data and other data set forth below for, and as of the end of the three month periods ended March 31, 2008 and 2009 have been derived from our unaudited consolidated financial statements and have been prepared on the same basis as the audited consolidated financial statements included elsewhere herein. In the opinion of management, the interim data reflect all adjustments, consisting only of normal and recurring adjustments, necessary for a fair presentation of results for these periods. Operating results for the three month period ended March 31, 2009 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2009.

	Year Ended December 31,									Three Months Ended March 31,						Twelve Months Ended March 31, 2009
	2006			2007			2008			2008			2009
	(dollars in thousands)
Statement of Operations Data:
Product revenues	$	1,822,141		$	1,970,106		$	2,224,704		$	543,261		$	563,080		$	2,244,523
Service revenues		989,242			1,030,672			1,079,473			267,346			279,481			1,091,608
Total revenues		2,811,383			3,000,778			3,304,177			810,607			842,561			3,336,131
Cost of products		1,753,638			1,925,547			2,163,943			532,027			551,585			2,183,501
Cost of services:
Operating compensation and benefits		458,006			479,177			523,939			130,188			137,640			531,391
Other operating costs		274,665			293,677			321,947			76,796			80,696			325,847
Depreciation and amortization		69,351			73,159			72,790			18,601			17,565			71,754
Total cost of services		802,022			846,013			918,676			225,585			235,901			928,992
Total cost of products and services		2,555,660			2,771,560			3,082,619			757,612			787,486			3,112,493
General and administrative expense		76,948			84,326			76,883			19,988			18,131			75,026
Impairment, restructuring and other charges, net		—			15,126			384,929			381,306			1,409			5,032
Depreciation and amortization		13,983			16,172			30,017			7,153			7,533			30,397
Total costs and expenses		2,646,591			2,887,184			3,574,448			1,166,059			814,559			3,222,948
Income (loss) from operations		164,792			113,594			(270,271	)		(355,452	)		28,002			113,183
Other income (expense):
Interest expense, net		(92,870	)		(95,342	)		(92,757	)		(24,200	)		(22,622	)		(91,179	)
Other income (expense), net		—			—			2,213			1,371			—			842
Income (loss) before income taxes		71,922			18,252			(360,815	)		(378,281	)		5,380			22,846
Income tax (provision) benefit		(27,509	)		(7,447	)		(6,351	)		922			(3,604	)		(10,877	)
Net income (loss)		44,413			10,805			(367,166	)		(377,359	)		1,776			11,969
Less: Net income attributable to non-controlling interests		(2,388	)		(3,619	)		(3,324	)		(715	)		(759	)		(3,368	)
Net income (loss) attributable to the Company	$	42,025		$	7,186		$	(370,490	)	$	(378,074	)	$	1,017		$	8,601
Other Financial Data:
EBITDA(1)	$	250,275		$	203,678		$	(165,361	)	$	(329,143	)	$	53,669		$	217,451
Adjusted EBITDA(2)		250,275			218,804			219,568			52,163			55,078			222,483
Capital Expenditures		82,571			90,850			88,743			23,624			16,047			81,166

1

	Fiscal Year Ended December 31,									Three Months Ended March 31,						Twelve Months Ended March 31, 2009
	2006			2007			2008			2008			2009
	(dollars in thousands)
Statement of Cash Flows Data:
Net cash provided by (used in)
Operating activities	$	43,639		$	198,030		$	141,487		$	50,864		$	31,027		$	121,650
Investing activities		(110,768	)		(93,170	)		(137,004	)		(57,416	)		(15,342	)		(94,930	)
Financing activities		223,058			(237,370	)		(49,263	)		(2,316	)		(11,318	)		(58,265	)
Balance Sheet Data:
Working capital	$	254,022		$	202,232		$	198,616		$	165,279		$	205,005
Total assets		2,359,982			2,208,650			1,842,853			1,887,973			1,809,697
Long term debt, excluding current maturities		1,069,664			1,031,569			1,061,133			1,056,498			1,053,867
Total liabilities		1,765,093			1,641,110			1,633,866			1,697,850			1,603,235
Total Company Stockholder’s equity		580,741			554,323			195,415			176,829			192,937
Key Operating Data:
Services Volume
Cancer centers (at end of period)		80			77			80			79			80
Medical oncology visits		9,793			10,028			10,816			10,572			11,274
Radiation treatments		2,698			2,719			2,732			2,731			2,678
PET systems (at end of period)		33			34			37			34			38
PET scans		163			180			207			193			219
New patients enrolled in research studies		2,723			3,050			3,447
Affiliated physicians (at end of period)		1,067			1,199			1,211			1,247			1,227
Physician practice affiliations		112			132			112			66			50
Recruited physicians		61			58			52			5			10

	Twelve Months Ended March 31, 2009
	(dollars in thousands)
Adjusted Credit Statistics(3)
Cash and cash equivalents (at end of period)	$	111,751
Secured Debt(4)		789,150
Total Debt(5)		1,095,745
Total Net Debt(6)		983,994
Interest Expense(7)
EBITDA		217,451
Adjusted EBITDA		222,483
Ratio of Secured Debt to Adjusted EBITDA		3.5x
Ratio of Total Debt to Adjusted EBITDA		4.9x
Ratio of Total Net Debt to Adjusted EBITDA		4.4x
Ratio of Adjusted EBITDA to interest expense

(1) EBITDA is net income before interest, taxes, depreciation, amortization (including amortization of stock-based compensation), and other (income) expense. We believe EBITDA is a commonly applied measurement of financial performance. Adjusted EBITDA represents EBITDA adjusted for the various items described below. EBITDA and Adjusted EBITDA do not represent income or cash flows from operations, as these terms are defined under generally accepted accounting principles, and should not be considered as an alternative to net income as an indicator of our operating performance or to cash flows as a measure of liquidity. We believe that EBITDA and Adjusted EBITDA are useful to investors, since it can provide investors with additional information that is not directly available in a GAAP presentation. Each gives investors an indication of our liquidity and financial condition and each is used in evaluating the value of companies in general and in evaluating the liquidity of companies, their debt service obligations and their ability to service their indebtedness. EBITDA and Adjusted

2

EBITDA are a key tool used by management in assessing business performance and financial condition both with respect to our business as a whole and with respect to individual sites or product lines. EBITDA and Adjusted EBITDA as presented herein are not necessarily comparable to similarly titled measures reported by other companies. See our Current Report on Form 8-K filed on June 4, 2009 and the Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2009, both of which been incorporated by reference herein. The following sets forth a reconciliation of EBITDA to net income (loss) and Adjusted EBITDA to EBITDA.

	Year Ended December 31,							Three Months Ended March 31,					Twelve Months Ended March 31, 2009
	2006		2007		2008			2008			2009
	(dollars in thousands)
Net income (loss)	$	44,413	$	10,805	$	(367,166	)	$	(377,359	)	$	1,776	$	11,969
Interest expense, net		92,870		95,342		92,757			24,200			22,622		91,179
Income tax provision (benefit)		27,509		7,447		6,351			(922	)		3,604		10,877
Depreciation and amortization		83,334		89,331		102,807			25,754			25,098		102,151
Amortization of stock compensation		2,149		753		2,103			555			569		2,117
Other (income) expense, net		—		—		(2,213	)		(1,371	)		—		(842	)
EBITDA	$	250,275	$	203,678	$	(165,361	)	$	(329,143	)	$	53,669	$	217,451
Impairment, restructuring and other charges		—		15,126		384,929			381,306			1,409		5,032
Adjusted EBITDA	$	250,275	$	218,804	$	219,568		$	52,163		$	55,078	$	222,483

(2) Adjusted EBITDA reflects EBITDA, less impairment, restructuring and other charges, net.

(3) These as adjusted statistics are calculated using historical financial data as adjusted to give effect to the offering of the notes and use of proceeds therefrom, as if each occurred on March 31, 2009, other than interest expense, EBITDA and the ratio of interest expense to EBITDA, which are calculated as if such transactions occurred on March 31, 2008.

(4) Secured debt consists of the notes offered hereby and our existing senior notes. There are no amounts outstanding under our existing senior secured revolving credit facility, which is also secured debt.

(5) Represents actual total debt of $1,067.4 million plus the notes offered hereby of $465.0 million less the amounts outstanding under our existing term loan of $436.7 million (which term loan is to be retired in connection with this offering).

(6) Represents total debt less cash and cash equivalents.

(7) Interest expense reflects the interest rate on the notes offered hereby and the revised interest rate on our existing senior secured revolving credit facility following the amendment to such facility entered into in connection with this offering. See “Description of Certain Other Indebtedness—Our Existing Senior Secured Revolving Credit Facility.” Each quarter point change in the assumed interest rate would result in a $1.2 million change in annual interest expense on the notes offered hereby.

3